Book a Demo
Brielle Benyon
Gray shield icon
Is this you?
Claim your profile.

Brielle Benyon

Journalist

AS SEEN ON
CURE Media Group

Preston's Summary

Brielle Benyon is a journalist and the assistant managing editor at CURE Magazine. She focuses on themes of accessibility, civil rights, diversity and inclusion, as well as gender issues, encompassing both men's and women's interests alongside LGBTQ+ topics. Brielle's work has been featured in Urology Times, OncLive, Drug Topics, Targeted Oncology, Cancer Network, Oncology Nursing News, and CURE Media Group.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Informative: 66 %
Data Driven: 33 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Accessibility
  • Civil Rights
  • Diversity & Inclusion
  • Gender Issues
  • LGBTQ+ Interest
  • Men's Interest
  • Women's Interest

Pitching Insights

Brielle Benyon's coverage focuses heavily on healthcare and pharmaceutical topics, particularly in the field of oncology. The articles she covers often include data citations and expert commentary, indicating a strong emphasis on evidence-based reporting.

Given this focus, Brielle would likely be responsive to pitches from experts in the fields of oncology, cancer treatment, clinical trials, breast cancer research, and MPNs (Myeloproliferative Neoplasms). Sources with access to recent data or those who can provide insightful commentary based on evidence are also likely to resonate well with her.

As there is no specified geographic focus for Brielle's coverage area, relevant information or expertise from any location could be suitable for pitching.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Articles

CURE Media Group

Page Not Found

Page Not Found

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.

© 2026 Intelligent Relations